Study of the Tolerability, Pharmacokinetics, and Pharmacodynamics of INS50589 Intravenous Infusion in Healthy Volunteers

Inclusion Criteria: * Have body mass index (BMI) between 18.5 kg/m2 and 35 kg/m2 and body weight no greater than 120 kg. * If female, must not be pregnant or lactating, and if of childbearing potential or sexually active, must use acceptable method of birth control. Exclusion Criteria: * Have clinically significant acute or chronic disease (e.g., coronary artery disease, diabetes, chronic renal insufficiency, asthma). * Have major surgery within eight weeks of dosing. * Have overt viral illness within four weeks of dosing. * Have tendency or history in family of tendency for bleeding. * Have clinically significant abnormalities on clinical laboratory tests (chemistry, hematology, urinalysis). * Have taken aspirin or any other non-steroidal anti-inflammatory drug (NSAID) within 10 days prior to admission to study facility. * Have ever taken or received any of the following for medical conditions: (antiplatelet compounds including clopidogrel, ticlopidine, dipyridamole, tirofiban, eptifibatide, abciximab, adenosine, and prostacyclin) or (anticoagulants including vitamin K antagonists, thrombin inhibitors, heparins, hirudin or related compounds, argatroban and factor Xa inhibitors) * Have a clinically significant ECG abnormality.